Interesting facts
Interesting Facts About 4-[4-(4-bromophenyl)-4-hydroxy-1-piperidyl]-1-(4-fluorophenyl)butan-1-one
This compound represents an intricate blend of organic chemistry and pharmacological potential, featuring a striking combination of functional groups that suggests diverse applications in medicinal chemistry. Known for its complex structure, this compound contains:
- Aromatic rings: The presence of both bromophenyl and fluorophenyl moieties contributes to its electronic properties, influencing reactivity and bioactivity.
- Hydroxyl group: The hydroxyl (-OH) group plays a crucial role in enhancing solubility and interacts with biological targets, making the compound potentially effective as a drug.
- Piperidine structure: The piperidine ring is a common feature in many pharmaceutical agents, often linked to the modulation of neurotransmitters and the central nervous system.
Potential Applications
This compound could have several remarkable applications in the field of medicine and biochemistry:
- Antidepressant properties: Compounds with similar structures have been studied for their effectiveness as antidepressants, particularly influencing serotonin pathways.
- Antipsychotic activity: The structural features suggest potential interaction with dopamine receptors, which could lead to antipsychotic effects.
- Novel therapeutic agents: Ongoing research investigates its role in targeting specific diseases due to its unique combination of bromine and fluorine substituents affecting pharmacodynamics.
“Chemistry is the art of conversion, and this compound exemplifies the beauty of transformation within molecular structures.” Such compounds not only serve as intriguing puzzles for chemists but also hold the promise of breakthroughs in therapeutic developments. As research progresses, the study of this compound may lead to innovative approaches in treating various mental health disorders.
Synonyms
bromperidol
10457-90-6
Impromen
Bromoperidol
Tesoprel
4-(4-(4-bromophenyl)-4-hydroxypiperidin-1-yl)-1-(4-fluorophenyl)butan-1-one
Bromperidolum
Bromperidolum [INN-Latin]
4-[4-(4-bromophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one
R 11333
EINECS 233-943-3
LYH6F7I22E
Impromen (TN)
NSC-759275
CC 2489
BRN 1552256
4-(4-(p-Bromophenyl)-4-hydroxypiperidino)-4'-fluorobutyrophenone
DTXSID0022690
R 11,333
4-(4-(4-Bromophenyl)-4-hydroxypiperidino)-4'-fluorobutyrophenone
Bromperidol [USAN:INN:BAN:JAN]
BROMPERIDOL [MI]
BROMPERIDOL [INN]
BROMPERIDOL [JAN]
BROMPERIDOL [USAN]
R-11333
BROMPERIDOL [MART.]
BROMPERIDOL [WHO-DD]
1-Butanone, 4-(4-(4-bromophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-
4-(4-(4-Bromophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanone
4-[4-(4-Bromophenyl)-4-hydroxy-1-piperidinyl]-1-(4-fluorophenyl)-1-butanone
DTXCID102690
BROMPERIDOL [EP MONOGRAPH]
4-(4-(p-Bromophenyl)-4-hydroxypiperidinol)-4'-fluorobutyrophenone
5-21-02-00382 (Beilstein Handbook Reference)
BUTYROPHENONE, 4-(4-(p-BROMOPHENYL)-4-HYDROXYPIPERIDINO)-4'-FLUORO-
NSC 759275
NCGC00016692-01
Azurene
CAS-10457-90-6
4-[4-(4-bromophenyl)-4-hydroxy-1-piperidyl]-1-(4-fluorophenyl)butan-1-one
Bromperidolum (INN-Latin)
BROMPERIDOL (MART.)
C21H23BrFNO2
BROMPERIDOL DECANOATE IMPURITY G [EP IMPURITY]
BROMPERIDOL (EP MONOGRAPH)
1-Butanone, 4-[4-(4-bromophenyl)-4-hydroxy-1-piperidinyl]-1-(4-fluorophenyl)-
4-[4-(p-Bromophenyl)-4-hydroxypiperidino]-4'-fluorobutyrophenone;4-[4-(p-Bromophenyl)-4-hydroxypiperidino]-4'-fluorobutyrophenone
SR-05000001811
BROMPERIDOL DECANOATE IMPURITY G (EP IMPURITY)
UNII-LYH6F7I22E
bromperidolo
Bromperidol; 4-[4-(4-Bromophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one
Prestwick_781
Bromperidol (Standard)
Prestwick0_000509
Prestwick1_000509
Prestwick2_000509
Prestwick3_000509
C-C 2489-21
SCHEMBL43755
BSPBio_000437
MLS002153852
CHEMBL28218
SPBio_002358
Bromperidol (JAN/USAN/INN)
BPBio1_000481
BDBM81484
CHEBI:31305
HY-B0901R
N05AD06
HMS1569F19
HMS2093J06
HMS2096F19
HMS2230O05
HMS3370C12
HMS3713F19
Pharmakon1600-01505972
CAS_2448
HY-B0901
NSC_2448
RYB91975
Tox21_110565
NSC759275
PDSP1_001125
PDSP2_001109
AKOS015914052
Tox21_110565_1
CCG-213579
DB12401
FB19339
NCGC00016692-02
NCGC00016692-05
NCGC00179558-01
MS-27369
SMR001233211
SBI-0206864.P001
DB-040551
NS00002733
D01101
F85189
EN300-19767176
L000662
Q4973749
SR-05000001811-1
SR-05000001811-3
BRD-K78643075-001-03-3
BRD-K78643075-001-06-6
BRD-K78643075-001-11-6
Bromperidol, European Pharmacopoeia (EP) Reference Standard
1-Butanone, 4-[4-(4-bromophenyl)-4-hydroxy-1-piperidyl]-1-(4-fluorophenyl)-
4-[4-(4-Bromo-phenyl)-4-hydroxy-piperidin-1-yl]-1-(4-fluoro-phenyl)-butan-1-one
4-[4-(4-bromophenyl)-4-hydroxy-1-piperidyl]-1-(4-fluorophenyl)-butan-1-one
233-943-3
4-[4-(4-Bromophenyl)-4-hydroxy-1-piperidinyl]-1-(4-fluorophenyl)-1-butanone;4-[4-(p-Bromophenyl)-4-hydroxypiperidino]-4'-fluoro-buty rophenone;Azurene
Solubility Insights for 4-[4-(4-bromophenyl)-4-hydroxy-1-piperidyl]-1-(4-fluorophenyl)butan-1-one
The solubility of the compound C21H23BrClFNO2 is influenced by its complex molecular structure, which features various functional groups. Understanding its solubility can be summarized as follows:
In conclusion, while the solubility of this compound will likely be greater in polar solvents due to its functional groups, the overall solubility behavior will also be shaped by interactions between its hydrophobic and hydrophilic parts. It's important to conduct empirical solubility tests for conclusive insights.